表紙:ホルムアルデヒド脱水素酵素:パイプライン製品の分析
市場調査レポート
商品コード
365807

ホルムアルデヒド脱水素酵素:パイプライン製品の分析

Formaldehyde Dehydrogenase - Pipeline Review, H2 2019

出版日: | 発行: Global Markets Direct | ページ情報: 英文 27 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.49円
ホルムアルデヒド脱水素酵素:パイプライン製品の分析
出版日: 2019年12月27日
発行: Global Markets Direct
ページ情報: 英文 27 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、ホルムアルデヒド脱水素酵素を標的とした治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

ホルムアルデヒド脱水素酵素 概要

治療薬の開発

  • 開発中の製品:開発段階別
  • 開発中の製品:治療領域別
  • 開発中の製品:症状別

パイプライン製品の概況

  • 後期段階の製品
  • 初期段階の製品

企業で開発中の製品

治療薬の評価

  • 単剤/併用治療薬の場合
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • Nivalis Therapeutics, Inc.
  • Saje Pharma, LLC

薬剤プロファイル

休止中のプロジェクト

開発が中止された製品

主なニュースおよびプレスリリース

付録

図表

図表

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Glenmark Pharmaceuticals Ltd, H2 2019
  • Pipeline by Saje Pharma LLC, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
目次
Product Code: GMDHC2172TDB

Summary

According to the recently published report 'Formaldehyde Dehydrogenase - Pipeline Review, H2 2019'; Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) pipeline Target constitutes close to 5 molecules.

Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Formaldehyde dehydrogenase (FDH) is a zinc-containing metalloenzyme that catalyzes the oxidation of formaldehyde to formate. Formaldehyde dehydrogenase decomposes S-nitrosoglutathione and indirectly regulates the level of cellular protein S-nitrosation. It plays important role in respiratory diseases such as asthma.

The report 'Formaldehyde Dehydrogenase - Pipeline Review, H2 2019' outlays comprehensive information on the Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Preclinical stages are 5 respectively. Report covers products from therapy areas Respiratory, Cardiovascular, Immunology, Gastrointestinal and Metabolic Disorders which include indications Inflammation, Crohn's Disease (Regional Enteritis), Diabetes, Idiopathic Pulmonary Fibrosis, Stroke, Asthma, Cardiac Arrest, Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure (Heart Failure), Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Non-Alcoholic Steatohepatitis (NASH) and Rheumatoid Arthritis.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46)
  • The report reviews Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Overview
  • Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Companies Involved in Therapeutics Development
  • Glenmark Pharmaceuticals Ltd
  • Saje Pharma LLC
  • Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Drug Profiles
  • Small Molecule to Inhibit GSNOR for Chronic Obstructive Pulmonary Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SPL-334 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SPL-334.1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SPL-850 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SPL-891.1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Dormant Products
  • Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Discontinued Products
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer